Mesenchymal Stem Cells Market: By Source (Bone Marrow, Peripheral Blood, Lung Tissue, Umbilical Cord Blood, Amniotic Fluids, Adipose Tissues, and Synovial Tissues), By Applications (Injuries, Drug Discovery, Cardiovascular Infraction and Others), By End User (Clinical Research Organizations, Biotechnological Companies, Medical Research Institutes, and Hospitals), and Geography

 

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Mesenchymal Stem Cells Market size was valued at USD 2.70 billion in 2021 and is expected to reach USD 6.20 billion by 2028, at a CAGR of 12.6% during the forecast period 2022-2028. Owing to increase in the prevalence of chronic diseases, degenerative, inflammatory, and autoimmune diseases. Scientific advancements and rising number of biotechnological companies across the globe are expected to propel the growth of the market. Additionally, enhancing application of mesenchymal stem cells for the treatment of chronic diseases, bone and cartilage diseases, and autoimmune diseases, the advantages of mesenchymal stem cells such as ease of isolation, high potential of regeneration and immunoregulatory nature and increasing demand for advanced healthcare facilities are expected to enhance the sale of mesenchymal stem cells market. The report on global market gives historical, current, and future market sizes (US$ Mn) on the basis of source, application, end user, and region. This report studies global mesenchymal stem cells market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities).

Mesenchymal Stem Cells Market Summary

Study Period

2023-29

Base Year

2022

CAGR

12.6%

Largest Market

Asia-Pacific

Fastest Growing Market

North-America
Mesenchymal Stem Cells Market

Divers: Increased Awareness about Umbilical Stem Cell Restraints: Expensive Procedures

Key Features of the Reports

  • Global market expanding at significant CAGR over 2022 to 2028 owing to rising prevalence of chronic disorders and rising advancements in technology for the development of new products and drugs
  • Based on application, cardiovascular segment of mesenchymal stem cells accounted for larger market revenue share in 2021 and projected to gain market revenue share over the forecast period
  • Players focusing on innovation of newer products and collaboration strategies to retain market position in global market

Mesenchymal Stem Cells Market Segmentation

Source of Isolation
  • Bone Marrow
  • Umbilical Cord Blood
  • Peripheral Blood
  • Lung Tissue
  • Synovial Tissues
  • Amniotic Fluids
  • Adipose Tissues
By Applications
  • Injuries
  • Drug Discovery
  • Cardiovascular Infraction
  • Others
End user
  • Clinical research organizations
  • Biotechnological companies,
  • Medical research institutes,
  • Hospitals

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  • Cell Applications, Inc. (USA)
  • Celprogen, Inc. (USA)
  • Cyagen US Inc. (USA)
  • Genlantis, Inc. (USA)
  • Lonza Group (Switzerland)
  • Mesoblast Limited (Australia)
  • MilliporeSigma (USA)
  • Neuromics (USA)
  • Orthofix International N.V. (Italy)
  • PromoCell GmbH (Germany)